Abstract: Objective This study aims to describe complications related to ventricular catheter systems with subcutaneous reservoirs (VCSR) (such as Ommaya reservoirs) in pediatric patients with brain tumors. Methods Retrospective analysis of consecutive patients with a total of 31 VCSR treated at the Children's University Hospital of Zurich, Switzerland. Results A total of 20 patients with a median age of 3.3 years at VCSR implantation received 31 VCSR. Overall, 19 complications in 11 patients were recorded: 7 patients had a VCSR-related infection with coagulase-negative staphylococci, 4 of these probably as a surgical complication and 3 probably related to VCSR use. Systemic perioperative prophylaxis was administered in 22 cases, and intraventricular vancomycin and gentamicin were given in 8 cases (none of which subsequently developed an infection). Other complications included wound dehiscence, catheter malplacement, and leakage of cerebrospinal fluid. Overall, 17 VCSR were explanted due to complications. Conclusion Infections were the most frequent VCSR-related complication. In our own institution, the high rate of complications led to the definition of a bundle of measures as a standard operating procedure for VCSR placement and use. Prospective studies in larger patient collectives are warranted to better identify risk factors and evaluate preventive measures such as the administration of perioperative antibiotics and the use of antimicrobial coating of catheters. 
Overt metastatic disease may be present already at diagnosis or at relapse. After surgery, adjuvant treatment of such tumors often includes radiotherapy and systemic chemotherapy. However, radiotherapy, especially craniospinal irradiation in young children, can lead to significant long-term sequelae, such as neuropsychological impairment or secondary malignancies, and penetration of chemotherapy into the CSF space is limited by the blood-brain barrier.(1-3) Therefore, several childhood brain tumor treatment protocols include intraventricular chemotherapy with drugs such as methotrexate, cytarabine, etoposide, and topotecan administered into the CSF space through a ventricular catheter system with a subcutaneous reservoir (VCSR) allowing to defer or obviate radiotherapy in some patients or to complement multimodal therapy in others. (4) (5) (6) (7) (8) The instillation of chemotherapy into a lateral ventricle using a VCSR such as the Ommaya reservoir offers several potential advantages compared to lumbar intrathecal injection. (9) It ensures a more uniform drug distribution within the CSF, requires a lower minimum thrombocyte count, and is more convenient for the patients, who generally do not need sedation or anesthesia. (10-11) However, the implantation and the use of VCSR may be associated with complications such as misplacement, intracerebral hemorrhage, and infection. Several series, most of them describing adult patients, found a large variability in complication rates, ranging from almost 0% to more than 40%. (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) The reasons for this strikingly wide range as well as the potential role preventive measures (e.g. perioperative antimicrobial prophylaxis or antimicrobial catheter impregnation) are still poorly understood. To study the incidence and nature of complications related to VCSR in patients with pediatric brain tumors, we conducted a retrospective analysis of 20 consecutive patients treated in our institution in whom a VCSR was implanted between 1996 and 2011.
METHODS
A retrospective study was undertaken on 591 consecutive children up to the age of 16 years with a primary brain tumor admitted to the University Children's Hospital of Zurich, Switzerland, from January 1980 to December 2011. Twenty-one of these patients received a VCSR, all of them between 1996 and 2011. One of these patients declined to participate in clinical trials; therefore, clinical information of 20 patients was extracted from the patient files and analyzed.
Intraventricular chemotherapy and intraventricular saline were filled into sterile syringes in a laminar flow hood by trained nurses. Application of chemotherapy to the VCSR was performed by 6 trained pediatric oncology consultants (in the majority of cases by 2 neuro-oncology consultants) as follows: All persons in the treatment room apart from the patient wore a mask and the physician performing the injection used sterile gloves; scalp hair growing above the reservoir was slightly shortened but not shaved; for disinfection a solution containing either propanol (mostly used in earlier patients) or a solution containing propanol + octenidine dihydrochloride (in later patients) was applied for six times, each time spirally wiping a soaked sterile cotton swab. The reservoir was punctured with a 22 Gauge
Huber needle connected to an empty syringe with a short connection tube, approximately 2 to 3 ml of CSF were aspirated and discarded, the chemotherapy agent (in most patients methotrexate) was administered, the system was flushed with approximately 2 ml aqueous sodium chloride solution (0.9%), and after removal of the needle the puncture site was covered with a sterile dry patch. VCSR- Kaplan-Meier estimates were used for the probability of VCSR survival (PVS) free of complicationrelated explantation with time for PVS measured from implantation to explantation or last follow-up, whichever came first, and indicated as percentage followed by the standard error. PVS were compared using the log-rank test. Table 1 and Table 2 . The median age at VCSR implantation Non-infectious complications included wound dehiscence in 6 (19%), catheter malplacement in 3 (10%), and CSF leakage and subcutaneous CSF collection in 1 (3%) case each, leading to explantation in all but the last patient. In another patient, who needed a ventriculoperitoneal (VP) shunt for a communicating hydrocephalus after tumor surgery as an emergency procedure, the VCSR, which had been placed two days before, was removed in the same procedure. Even though, in retrospect, removal might not have been necessary, it has been counted as a complication in this analysis.
The 1 year-probability of VCSR survival (PVS) without complication-related explantation was 48% (±9%) ( Table 4 and Figure 1A) , and the 1 year-PVS without infection-related explantation was 73% (±9%) ( Figure 1B ). When potential risk factors for infection were explored in univariable analyses using the log-rank test, administration of perioperative intraventricular antimicrobial prophylaxis emerged as the strongest protective factor (1 year-PVS free of infection of 100% vs. 66%[±11%], p=0.123) ( Figure   1C ).
DISCUSSION
Ventricular catheters with subcutaneous reservoirs (VCSR), such as the Ommaya reservoir, are used in children with brain tumors to deliver chemotherapy directly to the CSF space thereby overcoming the blood-brain barrier. Publications on VCSR-related complications, such as malplacement, hemorrhage, and infections related to surgery and to use, have described a large variability in complications rates in adult patients with cancer. (12-14, 16-18, 20, 22-23 ) However, literature on VCSR-related complications in children with brain tumors is scarce. (15, 19) We present a retrospective analysis of 20 consecutive patients with a total of 31 VCSR diagnosed at our institution between 1996 and 2011, describing the incidence and nature of VCSR-related complications and trying to identify predisposing factors.
We found a complication rate of 58% leading to the removal of 55% VCSR. While infections were the most common complications, others included wound dehiscence, malplacement, and cerebrospinal fluid leakage. The probability of 1-year VCSR survival (PVS) free of explantation due to complication was 48%. Our complication rate is higher than that of most other publications, including the two pediatric In accordance with most of the other series, the most frequent complications were infections (23% of VCSR), with four early infections (2 to 10 days after implantation) most probably as a complication of surgery and three later occurring infections (51 to 203 days after implantation), probably due to the use of the device. The 1-year PVS free of infection was 73%. The causative agents were coagulasenegative staphylococci in all cases, and according to our institutional policy, all VCSR were explanted and the patients were treated with systemic and/or intraventricular antibiotics. While the frequency of infectious complications shows a marked variation in other publications ranging from 0% to 30% in most cases, the uniformly most frequent causative agents are coagulase-negative staphylococci. More rarely, species such as P. acnes, S. aureus, E. faecalis, and P. aeruginosa have been described. with a combination of vancomycin and gentamicin, which offers a broad coverage of potential pathogens including coagulase-negative staphylococci.
To our knowledge, no thorough analyses of the influence of other protective measures or risk factors have been conducted. We could not detect any influence of other parameters such as age, neutrophil count at implantation, or number of injections into the reservoir, on the risk of infection, however due to the small sample size the power of these calculations is only very limited. While we found infections in 23% of VCSR, only one infection was reported in the series of Peyrl et al., which is the only publication on a patient collective comparable similar to ours. (19) A few institutional differences regarding implantation and use can be found: While in our institution systemic perioperative antimicrobial prophylaxis generally consists of a single dose of cefazolin as a perioperative prophylaxis, their patients received antibiotics for three to five days after surgery. We had not set any minimum interval between the VCSR implantation and its first use, whereas the first injection was not done earlier than 5 days postoperatively in their patients. Moreover, we used 22 Gauge Huber needle for injections as opposed to a thinner (25 Gauge) butterfly cannula, and whereas we didn't shave the scalp over the reservoir they did. Whether one or more of these differences has contributed to the higher frequency of infections in our patients, cannot be determined from available data.
Controversies exist regarding the optimum management of VCSR infections. While in all of our patients with overt VCSR infection the device was explanted at diagnosis of the complication, others have tried to rescue the VCSR using intravenous ± intraventricular antimicrobials with various rates of success. (13, 16-17, 24, 29) Whether a VCSR that is used anymore should be left in place or electively explanted is another still unanswered question. Whereas the existence of late infections occurring several years after the last use of the device (23, (30) (31) would serve as an argument in favor of explantation, the (non-quantified) risk of hemorrhage at explantation due to the adhesion of CNS/choroid plexus tissue to the catheter can be cited as a counterargument (even if ideally the implanted catheter tip does not reach the choroid plexus).
Non-infectious complications leading to VCSR explantation in our series included wound dehiscence, catheter malplacement, and CSF leakage. A subcutaneous CSF collection after VCSR implantation resolved spontaneously, and in one patient the VCSR was removed during ventriculo-peritoneal shunt implantation performed as an emergency procedure due to malresorptive hydrocephalus after tumor surgery. Wound dehiscence was not a frequent complication in other series. Possible preventive measures to avoid high traction on the suture may be the choice of small reservoir sizes in young children, the preparation of a sufficiently large subcutaneous pocket at implantation, and the avoidance of placement of the reservoir or the extracranial end of the catheter directly under the site of incision.
Catheter malplacement has been described as one of the more frequent complications by several other authors. (13, 16, (18) (19) (20) In one of our patients, the catheter had not been advanced far enough, so that the tip was located in the brain parenchyma. Nevertheless, aspiration of CSF was possible due to a communication with the external CSF space. In order to prevent instillation of chemotherapy into a choice of impregnated catheters encouraged; extra small reservoir size for young children and generous mobilization of skin at implantation to avoid skin traction; first puncture not earlier than 5 days after implantation; punctures if possible always by the same two neuro-oncologists, in any case only by trained senior oncology consultants; hair above reservoir carefully cut with scissors; masks for each person except for patient; closed door and windows during whole procedure; disinfection with a solution containing octenidine dihydrochloride and propanol as follows: six times spirally rubbing a soaked sterile cotton swab, thereafter applying a soaked sterile compress during 2 minutes before letting the skin dry completely; use of a non-coring 25 G needle connected to a sterile syringe with a short connection tube; aspiration of 2 ml of CSF, injection of chemotherapy, flushing with 2 ml saline using an industrially pre- 
